The results showed that MSCs can be genetically engineered to express cytokines and augment the immune response via enhancing CD4+ and CD8+ T-cell infiltration and then stimulating subsequent cascade immune networks; these modified MSCs can be exploited to a therapeutic advantage against gliomas. The gene discussed is CD8A; the disease is glioma.